A collaborative study released on June 25 reports the development of a novel therapeutic approach designed to selectively target Epidermal Growth Factor Receptor (EGFR) and other kinases within tumor microenvironments. The findings, published in Bioorganic Chemistry, suggest that this strategy could improve the efficacy of cancer treatments.
The research was conducted by scientists from the University of Eastern Finland, North Carolina State University, the University of North Carolina at Chapel Hill, and the University of Oslo. The team focused on addressing a key limitation in current tyrosine kinase inhibitor therapies: undesired inhibition of EGFR and related kinases in healthy tissues, which often leads to toxic side effects and narrows the drugs' therapeutic window.
To overcome these challenges, researchers explored a β-eliminative sulfone linker design for localized drug release from alginate hydrogels. Hydrolysis profiling showed that efficient parent drug release only occurred at basic pH levels, highlighting important constraints for depot formulations targeting mildly acidic tumor environments. In addition, they developed nitroreductase-activatable AQ-TKI prodrugs using nitroimidazole carbamate modifications to increase polarity and adjust solubility while preserving favorable pharmacokinetic properties. All prodrugs demonstrated chemical stability under physiologically relevant conditions and were efficiently uncaged by nitroreductase enzymes to regenerate active TKIs.
Molecular dynamics simulations and protein-ligand affinity predictions indicated that intact prodrugs had weakened binding affinities and reduced kinase target spaces compared to their parent compounds. This was consistent with higher IC₅₀ values observed in cell-free EGFR assays before activation, supporting reduced basal activity prior to enzymatic activation.
"The carbamate masking of 4-anilinoquinazoline TKIs enables controlled prodrug activation and reduces EGFR binding and basal activity. This proof-of-concept study demonstrates broad applicability to clinically used and investigational compounds. This work is a significant contribution to both the targeted therapy and the anti-cancer research field," said Professor Joshua Pierce of North Carolina State University.
